1 エグゼクティブ・サマリー
2 序文
2.1 概要
2.2 ステークホルダー
2.3 調査範囲
2.4 調査方法
2.4.1 データマイニング
2.4.2 データ分析
2.4.3 データの検証
2.4.4 リサーチアプローチ
2.5 リサーチソース
2.5.1 一次調査ソース
2.5.2 セカンダリーリサーチソース
2.5.3 前提条件
3 市場動向分析
3.1 はじめに
3.2 推進要因
3.3 抑制要因
3.4 機会
3.5 脅威
3.6 エンドユーザー分析
3.7 新興市場
3.8 Covid-19の影響
4 ポーターズファイブフォース分析
4.1 供給者の交渉力
4.2 買い手の交渉力
4.3 代替品の脅威
4.4 新規参入の脅威
4.5 競争上のライバル関係
5 治療抵抗性うつ病の世界市場（治療モダリティ別
5.1 はじめに
5.2 薬物療法
5.2.1 選択的セロトニン再取り込み阻害薬（SSRI）
5.2.2 セロトニン・ノルエピネフリン再取り込み阻害薬（SNRI）
5.2.3 三環系抗うつ薬（TCA）
5.2.4 モノアミン酸化酵素阻害薬（MAOI）
5.2.5 抗精神病薬
5.2.6 気分安定薬
5.2.7 ケタミンとエスケタミン
5.2.8 その他の薬物療法
5.3 心理療法
5.3.1 認知行動療法（CBT）
5.3.2 対人関係療法（IPT）
5.3.3 精神力動療法
5.3.4 その他の心理療法
5.4 神経刺激療法
5.4.1 経頭蓋磁気刺激（TMS）
5.4.2 脳深部刺激療法（DBS）
5.4.3 迷走神経刺激（VNS）
5.4.4 電気けいれん療法（ECT）
5.4.5 その他の神経刺激療法
5.5 組み合わせ療法
6 治療抵抗性うつ病の世界市場：流通チャネル別
6.1 導入
6.2 病院薬局
6.3 小売薬局
6.4 オンライン薬局
6.5 遠隔医療プラットフォーム
7 治療抵抗性うつ病の世界市場：エンドユーザー別
7.1 はじめに
7.2 病院
7.3 専門クリニック
7.4 外来診療所
7.5 研究機関
7.6 その他のエンドユーザー
8 治療抵抗性うつ病の世界市場：地域別
8.1 はじめに
8.2 北アメリカ
8.2.1 アメリカ
8.2.2 カナダ
8.2.3 メキシコ
8.3 ヨーロッパ
8.3.1 ドイツ
8.3.2 イギリス
8.3.3 イタリア
8.3.4 フランス
8.3.5 スペイン
8.3.6 その他のヨーロッパ
8.4 アジア太平洋
8.4.1 日本
8.4.2 中国
8.4.3 インド
8.4.4 オーストラリア
8.4.5 ニュージーランド
8.4.6 韓国
8.4.7 その他のアジア太平洋地域
8.5 南アメリカ
8.5.1 アルゼンチン
8.5.2 ブラジル
8.5.3 チリ
8.5.4 その他の南アメリカ地域
8.6 中東/アフリカ
8.6.1 サウジアラビア
8.6.2 アラブ首長国連邦
8.6.3 カタール
8.6.4 南アフリカ
8.6.5 その他の中東/アフリカ地域
9 主要開発
9.1 契約、パートナーシップ、コラボレーション、合弁事業
9.2 買収と合併
9.3 新製品上市
9.4 拡張
9.5 その他の主要戦略
10 企業プロフィール
10.1 AstraZeneca
10.2 Pfizer Inc.
10.3 GlaxoSmithKline plc
10.4 Eli Lilly and Company
10.5 Johnson & Johnson
10.6 Bristol-Myers Squibb Company
10.7 Forest Laboratories
10.8 Vistagen Therapeutics, Inc.
10.9 Novartis
10.10 AbbVie Inc.
10.11 H. Lundbeck A/S
10.12 Sandoz International GmbH
10.13 Otsuka Pharmaceutical Co., Ltd.
10.14 Par Pharmaceutical
10.15 Mylan N.V.
10.16 Aurobindo Pharma
10.17 Teva Pharmaceutical Industries Ltd.
表一覧
表1 治療抵抗性うつ病の世界市場展望、地域別（2022-2030年）（MNドル）
表2 治療抵抗性うつ病の世界市場展望、治療様式別（2022-2030年） （$MN）
表3 治療抵抗性うつ病の世界市場展望：薬物療法別（2022-2030年） （$MN）
表4 治療抵抗性うつ病の世界市場展望：選択的セロトニン再取り込み阻害薬（SSRI）別（2022-2030年） （$MN）
表5 治療抵抗性うつ病の世界市場展望、セロトニン・ノルエピネフリン再取り込み阻害薬（SNRI）別（2022-2030年）（MNドル）
表6 治療抵抗性うつ病の世界市場展望：三環系抗うつ薬（TCAs）（2022-2030年） （$MN）
表7 治療抵抗性うつ病の世界市場展望：モノアミン酸化酵素阻害薬（MAOI）（2022-2030年） （$MN）
表8 治療抵抗性うつ病の世界市場展望：抗精神病薬（2022-2030年） （$MN）
表9 治療抵抗性うつ病の世界市場展望、気分安定薬別 （2022-2030） （$MN）
表10 治療抵抗性うつ病の世界市場展望：ケタミン、エスケタミン別（2022-2030年） （$MN）
表11 治療抵抗性うつ病の世界市場展望、その他の薬物療法別 （2022-2030） （$MN）
表12 治療抵抗性うつ病の世界市場展望：精神療法別（2022-2030年） （$MN）
表13 治療抵抗性うつ病の世界市場展望：認知行動療法（CBT）別（2022-2030年） （$MN）
表14 治療抵抗性うつ病の世界市場展望：対人関係療法（IPT）別（2022-2030年） （$MN）
表15 治療抵抗性うつ病の世界市場展望、精神力動療法別（2022-2030年） （$MN）
表16 治療抵抗性うつ病の世界市場展望：その他の精神療法別（2022-2030年） （$MN）
表17 治療抵抗性うつ病の世界市場展望：神経刺激療法別（2022-2030年） （$MN）
表18 治療抵抗性うつ病の世界市場展望：経頭蓋磁気刺激療法（TMS）別（2022-2030年） （$MN）
表19 治療抵抗性うつ病の世界市場展望：脳深部刺激療法（DBS）別（2022-2030年） （$MN）
表20 治療抵抗性うつ病の世界市場展望、迷走神経刺激（VNS）別（2022-2030年） （$MN）
表21 治療抵抗性うつ病の世界市場展望、電気けいれん療法（ECT）別 （2022-2030） （$MN）
表22 治療抵抗性うつ病の世界市場展望、その他の神経刺激療法別 （2022-2030） （$MN）
表23 治療抵抗性うつ病の世界市場展望：併用療法別（2022-2030年） （$MN）
表24 治療抵抗性うつ病の世界市場展望：流通チャネル別（2022-2030年） （$MN）
表25 治療抵抗性うつ病の世界市場展望：病院薬局別（2022-2030年） （$MN）
表26 治療抵抗性うつ病の世界市場展望：小売薬局別（2022-2030年） （$MN）
表27 治療抵抗性うつ病の世界市場展望：オンライン薬局別（2022-2030年） （$MN）
表28 治療抵抗性うつ病の世界市場展望：遠隔医療プラットフォーム別（2022-2030年） （$MN）
表29 治療抵抗性うつ病の世界市場展望：エンドユーザー別（2022-2030年） （$MN）
表30 治療抵抗性うつ病の世界市場展望：病院別（2022-2030年） （$MN）
表31 治療抵抗性うつ病の世界市場展望：専門クリニック別（2022-2030年） （$MN）
表32 治療抵抗性うつ病の世界市場展望：外来診療所別（2022-2030年） （$MN）
表33 治療抵抗性うつ病の世界市場展望：研究機関別（2022-2030年） （$MN）
表34 治療抵抗性うつ病の世界市場展望：その他のエンドユーザー別 （2022-2030） （$MN）
注：北アメリカ、ヨーロッパ、APAC、南アメリカ、中東/アフリカ地域の表も上記と同様に表現しています。
According to data from a study published in the American Journal of Psychiatry in May 2024, the estimated 12-month prevalence of medication-treated major depressive disorder (MDD) in the United States was 8.9 million adults.
Market Dynamics:
Driver:
Increasing prevalence of depression
The rising prevalence of depression globally is a key driver for the treatment-resistant depression market. According to the World Health Organization, over 300 million people suffer from depression worldwide. As the number of depression cases increases, so does the subset of patients with treatment-resistant depression. This growing patient pool creates a larger market for advanced therapies and drives research and development efforts to find more effective treatments for this challenging condition.
Restraint:
High cost of treatment
The high cost of treatment for treatment-resistant depression poses a significant restraint on market growth. Novel therapies like ketamine infusions, transcranial magnetic stimulation, and esketamine nasal sprays are expensive and often not covered by insurance. For example, a course of ketamine infusions can cost thousands of dollars. These high out-of-pocket costs limit access to treatment for many patients and hinder widespread adoption of newer therapies, potentially slowing market expansion.
Opportunity:
Pipeline of novel therapies
The robust pipeline of novel therapies for treatment-resistant depression presents a significant market opportunity. Several promising compounds are in late-stage clinical trials, including psychedelics like psilocybin, new glutamatergic agents, and innovative drug combinations. For instance, COMP360 (psilocybin therapy) has shown positive results in phase 2 trials. The potential approval of these novel treatments could expand treatment options, improve outcomes, and drive market growth by addressing the unmet needs of treatment-resistant patients.
Threat:
Stringent regulatory environment
Regulatory agencies like the FDA require extensive clinical trial data and safety profiles for new drug approvals, especially for novel mechanisms of action. This rigorous process can lead to delays, increased development costs, and potential failures in bringing new treatments to market. The regulatory hurdles may discourage investment in innovative therapies and slow the pace of new treatment options becoming available.
Covid-19 Impact:
The COVID-19 pandemic has significantly impacted the treatment-resistant depression market. Lockdowns and social isolation have led to increased rates of depression and anxiety, potentially expanding the patient pool. Simultaneously, disruptions in healthcare access and clinical trials have affected treatment delivery and research progress. However, the pandemic has also accelerated the adoption of telemedicine and digital mental health solutions, opening new avenues for treatment delivery and market growth.
The retail pharmacies segment is expected to be the largest during the forecast period
The retail pharmacies segment is projected to dominate the treatment-resistant depression market during the forecast period. Retail pharmacies offer convenient access to prescription medications for patients with treatment-resistant depression. They play a crucial role in medication dispensing, patient education, and adherence support. The increasing availability of novel antidepressants and adjunctive therapies through retail channels contributes to this segment's growth. Additionally, the trend towards outpatient management of depression and the rising number of retail pharmacy chains globally further drive the expansion of this segment.
The neurostimulation segment is expected to have the highest CAGR during the forecast period
The neurostimulation segment is anticipated to experience the highest CAGR in the treatment-resistant depression market. This growth is driven by the increasing adoption of non-invasive brain stimulation techniques like transcranial magnetic stimulation (TMS) and electroconvulsive therapy (ECT). These methods offer alternative treatment options for patients who have not responded to traditional pharmacotherapy. The growing body of evidence supporting the efficacy of neurostimulation techniques, coupled with technological advancements improving their safety and tolerability, contributes to the rapid expansion of this segment.
Region with largest share:
During the forecast period, the North American region is expected to dominate the treatment-resistant depression market. North America's dominance can be attributed to factors such as the high prevalence of depression, well-established healthcare infrastructure, and early adoption of novel therapies. The region also benefits from significant research and development investments, the presence of key market players, and favorable reimbursement policies. Additionally, increased awareness about mental health and growing acceptance of innovative treatments contribute to North America's leading position in the market.
Region with highest CAGR:
During the forecast period, the Asia Pacific region is expected to witness rapid growth in the treatment-resistant depression market. This growth is driven by factors such as increasing awareness about mental health, improving healthcare infrastructure, and rising healthcare expenditure. The large population base and growing prevalence of depression in countries like China and India present significant market opportunities. Additionally, the expansion of pharmaceutical companies into the region and increasing government initiatives to address mental health issues contribute to the rapid market growth in Asia Pacific.
Key players in the market
Some of the key players in Treatment-Resistant Depression market include AstraZeneca, Pfizer Inc., GlaxoSmithKline plc, Eli Lilly and Company, Johnson & Johnson, Bristol-Myers Squibb Company, Forest Laboratories, Vistagen Therapeutics, Inc., Novartis, AbbVie Inc., H. Lundbeck A/S, Sandoz International GmbH, Otsuka Pharmaceutical Co., Ltd., Par Pharmaceutical, Mylan N.V., Aurobindo Pharma, and Teva Pharmaceutical Industries Ltd.
Key Developments:
In August 2024, AbbVie announced that it has completed its acquisition of Cerevel Therapeutics. With the completion of the acquisition, Cerevel is now part of AbbVie. ""AbbVie's acquisition of Cerevel strengthens our foundation in neuroscience and positions us to deliver sustainable long-term performance into the next decade and beyond,"" said Robert A. Michael, chief executive officer, AbbVie.
In July 2024, Johnson & Johnson announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval of SPRAVATO® (esketamine) CIII nasal spray as a monotherapy for adults living with treatment-resistant depression (TRD). Nearly 30 percent of the estimated 280 million people worldwide living with major depressive disorder (MDD) have TRD,1 which occurs when there is an inadequate response to two or more oral antidepressants during the same depressive episode.
In December 2022, AbbVie announced that the U.S. Food and Drug Administration (FDA) has approved VRAYLAR® (cariprazine) as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults. Supported by clinical data demonstrating efficacy and well-established tolerability, this additional indication provides a new option for adults who have a partial response to the treatment of an antidepressant.
Treatment Modalities Covered:
• Pharmacotherapy
• Psychotherapy
• Neurostimulation
• Combination Therapies
Distribution Channels Covered:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Telemedicine Platforms
End Users Covered:
• Hospitals
• Specialty Clinics
• Outpatient Clinics
• Research Institutes
• Other End Users
Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 End User Analysis
3.7 Emerging Markets
3.8 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Treatment-Resistant Depression Market, By Treatment Modality
5.1 Introduction
5.2 Pharmacotherapy
5.2.1 Selective Serotonin Reuptake Inhibitors (SSRIs)
5.2.2 Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
5.2.3 Tricyclic Antidepressants (TCAs)
5.2.4 Monoamine Oxidase Inhibitors (MAOIs)
5.2.5 Antipsychotics
5.2.6 Mood Stabilizers
5.2.7 Ketamine and Esketamine
5.2.8 Other Pharmacotherapies
5.3 Psychotherapy
5.3.1 Cognitive Behavioral Therapy (CBT)
5.3.2 Interpersonal Therapy (IPT)
5.3.3 Psychodynamic Therapy
5.3.4 Other Psychotherapies
5.4 Neurostimulation
5.4.1 Transcranial Magnetic Stimulation (TMS)
5.4.2 Deep Brain Stimulation (DBS)
5.4.3 Vagus Nerve Stimulation (VNS)
5.4.4 Electroconvulsive Therapy (ECT)
5.4.5 Other Neurostimulation Therapies
5.5 Combination Therapies
6 Global Treatment-Resistant Depression Market, By Distribution Channel
6.1 Introduction
6.2 Hospital Pharmacies
6.3 Retail Pharmacies
6.4 Online Pharmacies
6.5 Telemedicine Platforms
7 Global Treatment-Resistant Depression Market, By End User
7.1 Introduction
7.2 Hospitals
7.3 Specialty Clinics
7.4 Outpatient Clinics
7.5 Research Institutes
7.6 Other End Users
8 Global Treatment-Resistant Depression Market, By Geography
8.1 Introduction
8.2 North America
8.2.1 US
8.2.2 Canada
8.2.3 Mexico
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 Italy
8.3.4 France
8.3.5 Spain
8.3.6 Rest of Europe
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 New Zealand
8.4.6 South Korea
8.4.7 Rest of Asia Pacific
8.5 South America
8.5.1 Argentina
8.5.2 Brazil
8.5.3 Chile
8.5.4 Rest of South America
8.6 Middle East & Africa
8.6.1 Saudi Arabia
8.6.2 UAE
8.6.3 Qatar
8.6.4 South Africa
8.6.5 Rest of Middle East & Africa
9 Key Developments
9.1 Agreements, Partnerships, Collaborations and Joint Ventures
9.2 Acquisitions & Mergers
9.3 New Product Launch
9.4 Expansions
9.5 Other Key Strategies
10 Company Profiling
10.1 AstraZeneca
10.2 Pfizer Inc.
10.3 GlaxoSmithKline plc
10.4 Eli Lilly and Company
10.5 Johnson & Johnson
10.6 Bristol-Myers Squibb Company
10.7 Forest Laboratories
10.8 Vistagen Therapeutics, Inc.
10.9 Novartis
10.10 AbbVie Inc.
10.11 H. Lundbeck A/S
10.12 Sandoz International GmbH
10.13 Otsuka Pharmaceutical Co., Ltd.
10.14 Par Pharmaceutical
10.15 Mylan N.V.
10.16 Aurobindo Pharma
10.17 Teva Pharmaceutical Industries Ltd.
List of Tables
Table 1 Global Treatment-Resistant Depression Market Outlook, By Region (2022-2030) ($MN)
Table 2 Global Treatment-Resistant Depression Market Outlook, By Treatment Modality (2022-2030) ($MN)
Table 3 Global Treatment-Resistant Depression Market Outlook, By Pharmacotherapy (2022-2030) ($MN)
Table 4 Global Treatment-Resistant Depression Market Outlook, By Selective Serotonin Reuptake Inhibitors (SSRIs) (2022-2030) ($MN)
Table 5 Global Treatment-Resistant Depression Market Outlook, By Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) (2022-2030) ($MN)
Table 6 Global Treatment-Resistant Depression Market Outlook, By Tricyclic Antidepressants (TCAs) (2022-2030) ($MN)
Table 7 Global Treatment-Resistant Depression Market Outlook, By Monoamine Oxidase Inhibitors (MAOIs) (2022-2030) ($MN)
Table 8 Global Treatment-Resistant Depression Market Outlook, By Antipsychotics (2022-2030) ($MN)
Table 9 Global Treatment-Resistant Depression Market Outlook, By Mood Stabilizers (2022-2030) ($MN)
Table 10 Global Treatment-Resistant Depression Market Outlook, By Ketamine and Esketamine (2022-2030) ($MN)
Table 11 Global Treatment-Resistant Depression Market Outlook, By Other Pharmacotherapies (2022-2030) ($MN)
Table 12 Global Treatment-Resistant Depression Market Outlook, By Psychotherapy (2022-2030) ($MN)
Table 13 Global Treatment-Resistant Depression Market Outlook, By Cognitive Behavioral Therapy (CBT) (2022-2030) ($MN)
Table 14 Global Treatment-Resistant Depression Market Outlook, By Interpersonal Therapy (IPT) (2022-2030) ($MN)
Table 15 Global Treatment-Resistant Depression Market Outlook, By Psychodynamic Therapy (2022-2030) ($MN)
Table 16 Global Treatment-Resistant Depression Market Outlook, By Other Psychotherapies (2022-2030) ($MN)
Table 17 Global Treatment-Resistant Depression Market Outlook, By Neurostimulation (2022-2030) ($MN)
Table 18 Global Treatment-Resistant Depression Market Outlook, By Transcranial Magnetic Stimulation (TMS) (2022-2030) ($MN)
Table 19 Global Treatment-Resistant Depression Market Outlook, By Deep Brain Stimulation (DBS) (2022-2030) ($MN)
Table 20 Global Treatment-Resistant Depression Market Outlook, By Vagus Nerve Stimulation (VNS) (2022-2030) ($MN)
Table 21 Global Treatment-Resistant Depression Market Outlook, By Electroconvulsive Therapy (ECT) (2022-2030) ($MN)
Table 22 Global Treatment-Resistant Depression Market Outlook, By Other Neurostimulation Therapies (2022-2030) ($MN)
Table 23 Global Treatment-Resistant Depression Market Outlook, By Combination Therapies (2022-2030) ($MN)
Table 24 Global Treatment-Resistant Depression Market Outlook, By Distribution Channel (2022-2030) ($MN)
Table 25 Global Treatment-Resistant Depression Market Outlook, By Hospital Pharmacies (2022-2030) ($MN)
Table 26 Global Treatment-Resistant Depression Market Outlook, By Retail Pharmacies (2022-2030) ($MN)
Table 27 Global Treatment-Resistant Depression Market Outlook, By Online Pharmacies (2022-2030) ($MN)
Table 28 Global Treatment-Resistant Depression Market Outlook, By Telemedicine Platforms (2022-2030) ($MN)
Table 29 Global Treatment-Resistant Depression Market Outlook, By End User (2022-2030) ($MN)
Table 30 Global Treatment-Resistant Depression Market Outlook, By Hospitals (2022-2030) ($MN)
Table 31 Global Treatment-Resistant Depression Market Outlook, By Specialty Clinics (2022-2030) ($MN)
Table 32 Global Treatment-Resistant Depression Market Outlook, By Outpatient Clinics (2022-2030) ($MN)
Table 33 Global Treatment-Resistant Depression Market Outlook, By Research Institutes (2022-2030) ($MN)
Table 34 Global Treatment-Resistant Depression Market Outlook, By Other End Users (2022-2030) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
